CDEK
← All drugs Report issue

lampalizumab

mAbexperimental

Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy secondary to age-related macular degeneration. — Wikipedia

Clinical trial activity

7 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
6
Phase 3
3
Phase 4
0

Earliest trial started Sep 1, 2009 (NCT00973011)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • afd
  • afd
  • anti-factor-d
  • anti-fd
  • fcfd4514s
  • fcfd4514s
  • lampalizumab
  • lampalizumab
  • lampalizumab
  • rg-7417

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02745119Phase 3Jul 31, 2016Roche
NCT02288559Phase 2Mar 30, 2015Genentech, Roche
NCT02247531Phase 3Oct 6, 2014Roche
NCT02247479Phase 3Sep 1, 2014Roche
NCT01602120Phase 2May 31, 2012Genentech
NCT01229215Phase 2Feb 1, 2011Genentech
NCT00973011Phase 1Sep 1, 2009Genentech
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GenentechFor profit4422009
RocheFor profit4322014
2 organizations
Page 1 / 1